rdf:type |
|
lifeskim:mentions |
|
pubmed:issue |
10
|
pubmed:dateCreated |
2004-4-27
|
pubmed:abstractText |
Modification of the vanillyl substituent on a potent, semisynthetic lymphocyte function-associated antigen (LFA)-1/intercellular adhesion molecule (ICAM)-1 binding inhibitor of the statin family resulted in metabolically more stable analogues that displayed submicromolar inhibitory activity in vitro and considerable anti-inflammatory activity in vivo. The benzodioxole derivative 2b emerged with the best overall profile.
|
pubmed:language |
eng
|
pubmed:journal |
|
pubmed:citationSubset |
IM
|
pubmed:chemical |
|
pubmed:status |
MEDLINE
|
pubmed:month |
May
|
pubmed:issn |
0960-894X
|
pubmed:author |
|
pubmed:issnType |
Print
|
pubmed:day |
17
|
pubmed:volume |
14
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
2483-7
|
pubmed:meshHeading |
pubmed-meshheading:15109637-Animals,
pubmed-meshheading:15109637-Anti-Inflammatory Agents,
pubmed-meshheading:15109637-Dose-Response Relationship, Drug,
pubmed-meshheading:15109637-Drug Stability,
pubmed-meshheading:15109637-Humans,
pubmed-meshheading:15109637-Hydroxymethylglutaryl-CoA Reductase Inhibitors,
pubmed-meshheading:15109637-Inflammation,
pubmed-meshheading:15109637-Inhibitory Concentration 50,
pubmed-meshheading:15109637-Intercellular Adhesion Molecule-1,
pubmed-meshheading:15109637-Lovastatin,
pubmed-meshheading:15109637-Lymphocyte Function-Associated Antigen-1,
pubmed-meshheading:15109637-Microsomes, Liver,
pubmed-meshheading:15109637-Protein Binding,
pubmed-meshheading:15109637-Rats,
pubmed-meshheading:15109637-Structure-Activity Relationship
|
pubmed:year |
2004
|
pubmed:articleTitle |
Statin-derived 1,3-oxazinan-2-ones as submicromolar inhibitors of LFA-1/ICAM-1 interaction: stabilization of the metabolically labile vanillyl side chain.
|
pubmed:affiliation |
Novartis Institutes for Biomedical Research, A-1235 Vienna, Austria. thomas.ullrich@pharma.novartis.com
|
pubmed:publicationType |
Journal Article
|